At what pace is the non-alcoholic steatohepatitis (nash) market growing, and what is its estimated value?
The non-alcoholic steatohepatitis (NASH) market size has grown exponentially in recent years. It will grow from $4.5 billion in 2024 to $6.13 billion in 2025 at a compound annual growth rate (CAGR) of 36.1%. The growth in the historic period can be attributed to rising prevalence of NASH, obesity epidemic, growing awareness and diagnoses, shift in lifestyle and dietary patterns, healthcare infrastructure development.
The non-alcoholic steatohepatitis (NASH) market size is expected to see exponential growth in the next few years. It will grow to $19.07 billion in 2029 at a compound annual growth rate (CAGR) of 32.8%. The growth in the forecast period can be attributed to advancements in NASH drug development, increasing NASH screening initiatives, rising healthcare expenditure, collaborative research efforts, government support and regulations. Major trends in the forecast period include focus on lifestyle interventions and patient education, increased collaboration in clinical research, regulatory advancements and pathway designations, integration of artificial intelligence in diagnosis and monitoring.
Get Your Free Sample of The Global Non-Alcoholic Steatohepatitis (NASH) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp
How have varous drivers impacted the growth of the non-alcoholic steatohepatitis (nash) market?
The rising cases of obesity is driving the demand for the non-alcoholic steatohepatitis (NASH) market going forward. Obesity is an aberrant or excessive fat build-up that poses a health concern, as well as body weight that is higher than what is deemed healthy or typical for a person of a specific height. As non-alcoholic fatty liver disease has become more prevalent due to the rising obesity pandemic, NASH may become the most widespread cause of severe liver disease in the ensuing decades, therefore, driving need for NASH treatment and related drugs. For instance, in March 2024, according to the World Health Organization (WHO), a UK-based international public health organization, in 2022, approximately 2.5 billion adults aged 18 and older were classified as overweight, with 890 million of them living with obesity. Therefore, the rise in the cases of obesity will drive the growth of the non-alcoholic steatohepatitis (NASH) market.
What are the primary segments of the non-alcoholic steatohepatitis (nash) market?
The non-alcoholic steatohepatitis (NASH) market covered in this report is segmented –
1) By Type: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral
Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms
Order your report now for swift delivery
Which firms are leading the non-alcoholic steatohepatitis (nash) market?
Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.
How will industry trends affect the trajectory of the non-alcoholic steatohepatitis (nash) market?
Major companies operating in the non-alcoholic steatohepatitis (NASH) market are developing thyroid hormone receptor-beta (THR-beta) agonists to enhance liver metabolism, reduce liver fat accumulation, and improve liver function. Thyroid hormone receptor-beta (THR-beta) agonists are compounds that selectively activate the thyroid hormone receptor-beta subtype, which is a key receptor involved in the regulation of metabolism, growth, and development. For instance, in March 2024, the Food and Drug Administration, a US-based regulatory body, approved Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist as the first treatment for adults with noncirrhotic NASH with moderate to advanced liver scarring (fibrosis). By selectively activating the THR-beta receptor, Rezdiffra helps regulate lipid metabolism, leading to a reduction in intrahepatic triglycerides and overall liver fat accumulation.
Which geographic trends are shaping the non-alcoholic steatohepatitis (nash) market, and which region has the highest market share?
The countries covered in the non-alcoholic steatohepatitis (nash) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
What Does The Non-Alcoholic Steatohepatitis (NASH) Market Report 2025 Offer?
The non-alcoholic steatohepatitis (nash) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Non-alcoholic steatohepatitis (NASH) is a severe case of fatty liver disease that is characterized by inflammation of the liver and can proceed to cirrhosis and liver failure.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8805
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
